Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver
- PMID: 15213625
- PMCID: PMC1356381
- DOI: 10.1097/01.sla.0000129672.51886.44
Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver
Abstract
Objective: We sought to compare the experience of 2 different surgical units in the treatment of hepatocellular carcinoma (HCC) on cirrhosis with resection or percutaneous radiofrequency ablation (RFA), respectively.
Summary background data: When allowed by the hepatic functional reserve, surgery is the therapy for HCC on cirrhosis; alternative treatments are proposed because of the high tumor recurrence rate after resection. RFA is being widely adopted to treat HCC.
Methods: Over a 4-year period, 79 cirrhotics with HCC underwent resection in 1 surgical unit (group A) and another 79 had RFA at a different unit (group B). Patient selection, operative mortality, hospital stay, and 1- and 3-year overall and disease-free survival were analyzed.
Results: Group A (surgery): mean follow-up was 28.9 +/- 17.9 months; operative mortality was 3.8%, mean hospital stay 9 days; 1- and 3-year survival were, respectively, 83 and 65%. One- and 3-year disease-free survival were 79 and 50%. Group B (RFA): mean follow-up was 15.6 +/- 11.7 months. Mean hospital stay was 1 day (range 1-8). One- and 3-year survival were 78 and 33%; 1- and 3-year disease-free survival were 60 and 20%. Overall and disease-free survival were significantly higher in group A (P = 0.002 and 0.001). The advantage of surgery was more evident for Child-Pugh class A patients and for single tumors of more than 3 cm in diameter. Results were similar in 2 groups for Child-Pugh class B patients
Conclusions: RFA has still to be confirmed as an alternative to surgery for potentially-resectable HCCs.
Figures


Similar articles
-
Surgical resection versus radiofrequency ablation for small hepatocellular carcinomas within the Milan criteria.J Hepatobiliary Pancreat Surg. 2009;16(3):359-66. doi: 10.1007/s00534-009-0069-7. Epub 2009 Mar 20. J Hepatobiliary Pancreat Surg. 2009. PMID: 19300896
-
Radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma in cirrhosis.J Gastrointest Surg. 2008 Jan;12(1):192-8. doi: 10.1007/s11605-007-0392-8. Epub 2007 Nov 13. J Gastrointest Surg. 2008. PMID: 17999123
-
Minimally invasive surgery versus radiofrequency ablation for single subcapsular hepatocellular carcinoma ≤ 2 cm with compensated liver cirrhosis.Surg Endosc. 2020 Dec;34(12):5566-5573. doi: 10.1007/s00464-019-07357-x. Epub 2020 Jan 28. Surg Endosc. 2020. PMID: 31993821
-
Meta-analysis of the therapeutic effect of hepatectomy versus radiofrequency ablation for the treatment of hepatocellular carcinoma.Surg Laparosc Endosc Percutan Tech. 2010 Jun;20(3):130-40. doi: 10.1097/SLE.0b013e3181d823df. Surg Laparosc Endosc Percutan Tech. 2010. PMID: 20551807 Review.
-
The laparoscopic approach for radiofrequency ablation of hepatocellular carcinoma--indication, technique and results.Langenbecks Arch Surg. 2013 Jan;398(1):47-53. doi: 10.1007/s00423-012-1018-5. Epub 2012 Oct 24. Langenbecks Arch Surg. 2013. PMID: 23093087 Review.
Cited by
-
Therapeutic Approach to Post-Transplant Recurrence of Hepatocellular Carcinoma: Certainties and Open Issues.Cancers (Basel). 2023 Nov 26;15(23):5593. doi: 10.3390/cancers15235593. Cancers (Basel). 2023. PMID: 38067299 Free PMC article. Review.
-
Efficacy of RetroNectin-activated cytokine-induced killer cell therapy in the treatment of advanced hepatocelluar carcinoma.Oncol Lett. 2016 Jul;12(1):707-714. doi: 10.3892/ol.2016.4629. Epub 2016 May 25. Oncol Lett. 2016. PMID: 27347204 Free PMC article.
-
Radiofrequency ablation vs. surgical resection for resectable hepatocellular carcinoma: A systematic review and meta-analysis.Mol Clin Oncol. 2020 Jan;12(1):15-22. doi: 10.3892/mco.2019.1941. Epub 2019 Oct 31. Mol Clin Oncol. 2020. PMID: 31814972 Free PMC article.
-
Stereotactic Body Radiation Therapy With or Without Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone in Early-Stage Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.J Gastrointest Cancer. 2023 Dec;54(4):1058-1070. doi: 10.1007/s12029-023-00940-5. Epub 2023 Jun 12. J Gastrointest Cancer. 2023. PMID: 37306936
-
Preoperative predictors of short-term survival after hepatectomy for multinodular hepatocellular carcinoma.World J Gastroenterol. 2012 Jul 7;18(25):3272-81. doi: 10.3748/wjg.v18.i25.3272. World J Gastroenterol. 2012. PMID: 22783052 Free PMC article.
References
-
- Martin P. Hepatocellular carcinoma: risk factors and natural history. Liver Transpl Surg. 1998;4(Suppl 1):87–91. - PubMed
-
- Yamamoto J, Kosuge T, Takyama T, et al. Recurrence of hepatocellular carcinoma after surgery. Br J Surg. 1996;83:1219–1222. - PubMed
-
- Wall JW, Marotta PJ. Surgery and transplantation for hepatocellular carcinoma. Liver Transpl. 2000;6:S16–S22. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical